肿瘤边缘与ADC变化在不可切除肝细胞癌首次TACE后确定需额外治疗中的作用
回顾性队列纳入180例2005-2016年接受TACE作为初始治疗的不可切除肝细胞癌患者,按肿瘤边缘(清晰vs不清晰)和清晰组ADC变化(ΔADC阈值25%)分三组。不清晰组生存更差(HR=1.95,p<0.001),多次TACE与生存改善相关(HR=0.88,p=0.033),≥4次TACE后改善显著。清晰组中ADC应答者(ΔADC≥25%)生存最长,多次TACE与其生存无关;ADC无应答者多次TACE与更长生存相关(HR=0.79,p=0.034),≥3次TACE后改善显著。
要点
- 基线肿瘤边缘不清晰者生存更差(HR=1.95,p<0.001),多次TACE与生存改善相关,≥4次后显著改善。
- 边缘清晰且首次TACE后ADC应答(ΔADC≥25%)者生存最长,多次TACE与其生存无显著相关(HR=1.004,p=0.982)。
- 边缘清晰且ADC无应答(ΔADC<25%)者多次TACE与更长生存相关(HR=0.79,p=0.034),≥3次后显著改善。
核心结论
- 序贯TACE的生存获益因肝细胞癌亚组而异。
- 对首次TACE有应答的边缘清晰病灶,多次TACE无显著生存获益。
- 生存获益最大为ADC无应答的边缘清晰组,最小为不清晰组,与ADC应答无关。
研究设计与样本
- 回顾性队列研究,纳入180例2005-2016年间接受TACE作为不可切除肝细胞癌初始治疗的患者。
- 由两名放射科医生在基线判定肿瘤边缘(清晰vs不清晰)。
- 边缘清晰组按%ADC变化(ΔADC阈值25%)分为ADC应答者与ADC无应答者。
- 据此将患者分为三组:边缘不清晰组、边缘清晰ADC应答组、边缘清晰ADC无应答组。
- 采用Cox分析比较不同组多次TACE的生存获益。
关键影像表现/征象
- 肿瘤边缘分为清晰与不清晰两类,由两名放射科医生在基线判定。
- 边缘不清晰组108例,生存更差(HR=1.95,p<0.001)。
- 边缘清晰组72例,按ΔADC阈值25%分为ADC应答者(ΔADC≥25%)与ADC无应答者(ΔADC<25%)。
诊断标准与关键数值
- ΔADC阈值定为25%,用于将边缘清晰组分为ADC应答者(ΔADC≥25%)与ADC无应答者(ΔADC<25%)。
- 边缘不清晰组多次TACE与总生存改善相关(HR=0.88,p=0.033),≥4次TACE后生存改善显著。
- 边缘清晰组多次TACE与总生存改善无显著相关(HR=0.181,p=0.090)。
- ADC应答者(ΔADC≥25%)生存长于其他组(p=0.015),多次TACE与其总生存无显著相关(HR=1.004,p=0.982)。
- ADC无应答者(ΔADC<25%)TACE次数增加与总生存显著延长相关(HR=0.79,p=0.034),≥3次TACE后总生存显著改善。
临床应用与阅片要点
- 基线肿瘤边缘与首次TACE后ADC变化可用于区分序贯TACE生存获益不同的肝细胞癌亚组。
- 边缘不清晰者多次TACE与生存改善相关,≥4次TACE后改善显著。
- 边缘清晰且ADC应答者多次TACE无显著生存获益。
- 边缘清晰且ADC无应答者多次TACE与生存延长相关,≥3次TACE后改善显著。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To define the number of TACE sessions needed to improve patients' overall survival (OS) in different subgroups of unresectable HCC.
METHODS: This retrospective cohort included 180 patients who got TACE between 2005-2016 as the initial treatment for unresectable HCC. Tumor margin (well- vs. ill-defined) was determined by two radiologists at baseline. Well-defined group was divided into two groups (ADC-responders vs. ADC-nonresponders) based on %ADC change (ΔADC-cutoff = 25 %). Accordingly, patients were categorized into three groups, ill-defined, well-defined ADC-responders, or well-defined ADC-nonresponders. Cox-analysis was used to compare the survival benefit of multiple TACE in different groups.
RESULTS: Ill-defined HCC (n = 108) was associated with worse survival (HR = 1.95,p < 0.001). Multiple TACE were associated with increased OS (HR = 0.88,p = 0.033) in these patients, with significant survival improvement after ≥4TACE. ΔADC was not related to OS in ill-defined group. In well-defined group (n = 72), multiple TACE were not associated with improved OS (HR = 0.181,p = 0.090). These patients were categorized into two groups based on ΔADC-cutoff. ADC-responders (ΔADC≥25 %) had the longest survival than other groups(p = 0.015). Multiple TACE sessions were not associated with better OS in this group (HR = 1.004,p = 0.982). By contrast, incremental number of TACE were associated with significantly longer OS in ADC-nonresponders (ΔADC<25 %) (HR = 0.79,p = 0.034). These patients' OS significantly improved after ≥3TACE.
CONCLUSION: The survival benefit of sequential TACE sessions varies for different HCC subgroups. There was no significant survival benefit associated with multiple TACE in well-defined lesions responding to the first TACE. The most survival benefit was for ADC-nonresponder well-defined group and it was least for ill-defined HCC group, regardless of ADC-response.
引用
- Shaghaghi M, AliyariG Hasabeh M, Ameli S, et al. Role of tumor margin and ADC change in defining the need for additional treatments after the first TACE in patients with unresectable HCC. Eur J Radiol. 2020. PMID: 33166831. doi:10.1016/j.ejrad.2020.109389
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。